Survival Benefit May Position Zaltrap To Compete With Avastin In Second-Line CRC

Full results of the trial will show how Sanofi-Aventis/Regeneron's VEGF Trap performs in patients who have been on Avastin, as well as how the survival advantage stacks up against Avastin.